Amprion working to expand access globally to alpha-synuclein protein test
WHY IT MATTERS
Patients with suspected Parkinson's disease or similar conditions may gain access to a diagnostic test that can identify their specific condition earlier, potentially allowing for treatment to start sooner.
A company called Amprion is partnering with a university in Australia to make their alpha-synuclein test more available around the world. This test detects abnormal proteins in the brain that can help doctors diagnose Parkinson's disease and related conditions earlier and more accurately.
Amprion is partnering with Macquarie University in Australia to expand access to its SAAmplify-alphaSYN test, which detects abnormal alpha-synuclein protein in people with suspected neurodegenerative diseases. The test can help diagnose Parkinson’s disease early, as well as help identify specific types of atypical parkinsonism, such as dementia with Lewy bodies (DLB) or Alzheimer’s with Lewy […] The post Amprion working to expand access globally to alpha-synuclein protein test appear